342 related articles for article (PubMed ID: 27725193)
41. Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.
Alliegro M; Ferla R; Nusco E; De Leonibus C; Settembre C; Auricchio A
Mol Ther; 2016 Dec; 24(12):2054-2063. PubMed ID: 27658524
[TBL] [Abstract][Full Text] [Related]
42. Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement.
Sevin C; Deiva K
Front Mol Biosci; 2021; 8():624988. PubMed ID: 34604300
[TBL] [Abstract][Full Text] [Related]
43. An update on gene therapy for lysosomal storage disorders.
Nagree MS; Scalia S; McKillop WM; Medin JA
Expert Opin Biol Ther; 2019 Jul; 19(7):655-670. PubMed ID: 31056978
[TBL] [Abstract][Full Text] [Related]
44. Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients.
Schwab ME; Brown JEH; Lianoglou B; Jin C; Conroy PC; Gallagher RC; Harmatz P; MacKenzie TC
Orphanet J Rare Dis; 2022 Jan; 17(1):25. PubMed ID: 35093147
[TBL] [Abstract][Full Text] [Related]
45. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
Seregin SS; Amalfitano A
Curr Pharm Des; 2011; 17(24):2558-74. PubMed ID: 21774776
[TBL] [Abstract][Full Text] [Related]
46. ERT Degrades Gene Therapy for Storage Disorder.
Markusic DM
Mol Ther; 2019 Jul; 27(7):1207-1208. PubMed ID: 31202634
[No Abstract] [Full Text] [Related]
47. Evolving therapies in neuronopathic LSDs: opportunities and challenges.
Rajan DS; Escolar ML
Metab Brain Dis; 2022 Oct; 37(7):2245-2256. PubMed ID: 35442005
[TBL] [Abstract][Full Text] [Related]
48. Non-neuronopathic lysosomal storage disorders: Disease spectrum and treatments.
Pastores GM; Hughes DA
Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):173-82. PubMed ID: 25987171
[TBL] [Abstract][Full Text] [Related]
49. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.
Brooks DA
Mol Genet Metab; 1999 Oct; 68(2):268-75. PubMed ID: 10527678
[TBL] [Abstract][Full Text] [Related]
50. Lysosomal storage disorders: old diseases, present and future challenges.
Klein AD; Futerman AH
Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():59-63. PubMed ID: 24380123
[TBL] [Abstract][Full Text] [Related]
51. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.
Sly WS; Vogler C
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):5760-2. PubMed ID: 11983877
[No Abstract] [Full Text] [Related]
52. Treating lysosomal storage disorders: current practice and future prospects.
Platt FM; Lachmann RH
Biochim Biophys Acta; 2009 Apr; 1793(4):737-45. PubMed ID: 18824038
[TBL] [Abstract][Full Text] [Related]
53. [Application of adeno-associated virus-mediated gene therapy in lysosomal storage diseases].
Lin XQ; Wang XL; Peng J
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Nov; 24(11):1281-1287. PubMed ID: 36398557
[TBL] [Abstract][Full Text] [Related]
54. Role of induced pluripotent stem cells in lysosomal storage diseases.
Kido J; Nakamura K; Era T
Mol Cell Neurosci; 2020 Oct; 108():103540. PubMed ID: 32828964
[TBL] [Abstract][Full Text] [Related]
55. [Therapy of lysosomal storage diseases: update and perspectives].
Lara-Aguilar RA; Juárez-Vázquez CI; Medina-Lozano C
Rev Invest Clin; 2011; 63(6):651-8. PubMed ID: 23650678
[TBL] [Abstract][Full Text] [Related]
56. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.
Parenti G
EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Approaches in Lysosomal Storage Diseases.
Fernández-Pereira C; San Millán-Tejado B; Gallardo-Gómez M; Pérez-Márquez T; Alves-Villar M; Melcón-Crespo C; Fernández-Martín J; Ortolano S
Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944420
[TBL] [Abstract][Full Text] [Related]
58. Lysosomal storage disorders affecting the heart: a review.
Nair V; Belanger EC; Veinot JP
Cardiovasc Pathol; 2019; 39():12-24. PubMed ID: 30594732
[TBL] [Abstract][Full Text] [Related]
59. Therapies for neurological disease in the mucopolysaccharidoses.
Anson DS; McIntyre C; Byers S
Curr Gene Ther; 2011 Apr; 11(2):132-43. PubMed ID: 21291356
[TBL] [Abstract][Full Text] [Related]
60. Gene therapy for the neurological manifestations in lysosomal storage disorders.
Cheng SH
J Lipid Res; 2014 Sep; 55(9):1827-38. PubMed ID: 24683200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
